Pre-clinical studies were undertaken in mice tumor models, where VEGFR-2 and PD-L1 monotherapies induced both unique and overlapping patterns of immune gene expression, and combination therapy resulted in an enhanced immune activation signature explaining the enhanced clinical activity observed in the combined blockade of VEGFR-2 and PD-1-axis pathways [42]. The gene discussed is CD274; the disease is neoplasm.